Consistent with this, decreased levels of ATR and treatment with ATR inhibitors (ATRi), presently being tested in phase I–II clinical trials, suppress tumour growth [22–25], whereas an extra copy of Chk1 facilitates cellular transformation [26]. Here, ATR is linked to neoplasm.